JP2005325108A5 - - Google Patents

Download PDF

Info

Publication number
JP2005325108A5
JP2005325108A5 JP2005119011A JP2005119011A JP2005325108A5 JP 2005325108 A5 JP2005325108 A5 JP 2005325108A5 JP 2005119011 A JP2005119011 A JP 2005119011A JP 2005119011 A JP2005119011 A JP 2005119011A JP 2005325108 A5 JP2005325108 A5 JP 2005325108A5
Authority
JP
Japan
Prior art keywords
pain
mmhg
decrease
rats
threshold
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2005119011A
Other languages
English (en)
Other versions
JP2005325108A (ja
JP4892857B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2005119011A priority Critical patent/JP4892857B2/ja
Priority claimed from JP2005119011A external-priority patent/JP4892857B2/ja
Publication of JP2005325108A publication Critical patent/JP2005325108A/ja
Publication of JP2005325108A5 publication Critical patent/JP2005325108A5/ja
Application granted granted Critical
Publication of JP4892857B2 publication Critical patent/JP4892857B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Description

［実験結果］水浸飼育による痛み閾値低下に対する山帰来の作用
正常（疑似手術）ラット及びＯＶＸラットの痛み閾値はそれぞれ１８８±１７ｍｍＨｇ及び１５８±２０ｍｍＨｇであり、ＯＶＸのみでは、痛み閾値の差は生じなかった。これらラットを水浸飼育すると痛み閾値がそれぞれ低下し、その値は１３３±２７ｍｍＨｇ（２９％低下）及び６９±８ｍｍＨｇ（５６％低下）であり、ＯＶＸラットが疲労及びストレスを複合的に曝されることにより、痛みに対する反応が増していることが確認された。ＯＶＸラットのこの痛み閾値低下に対して、エストラジオール０．１ｍｇ／ｋｇ（経口）は有意に抑制し、この痛みに対する行動変化がホルモンバランスを整えることにより改善されることが明らかとなった。これに対して、山帰来末１０００ｍｇ／ｋｇはこの痛み閾値の低下を抑制した（図６参照）。これらのことから、山帰来は、痛みを過敏に感じる女性にとって、痛みが主訴となる肩こり、頭痛、腰痛などの痛みの緩和に有効であることが考えられた。
JP2005119011A 2004-04-15 2005-04-15 更年期症の予防又は改善剤 Expired - Fee Related JP4892857B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2005119011A JP4892857B2 (ja) 2004-04-15 2005-04-15 更年期症の予防又は改善剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004120864 2004-04-15
JP2004120864 2004-04-15
JP2005119011A JP4892857B2 (ja) 2004-04-15 2005-04-15 更年期症の予防又は改善剤

Publications (3)

Publication Number Publication Date
JP2005325108A JP2005325108A (ja) 2005-11-24
JP2005325108A5 true JP2005325108A5 (ja) 2008-04-17
JP4892857B2 JP4892857B2 (ja) 2012-03-07

Family

ID=35471741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005119011A Expired - Fee Related JP4892857B2 (ja) 2004-04-15 2005-04-15 更年期症の予防又は改善剤

Country Status (1)

Country Link
JP (1) JP4892857B2 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014091700A (ja) * 2012-11-02 2014-05-19 Kao Corp Ｇｌｐ−１分泌促進剤
JP2022071835A (ja) * 2020-10-28 2022-05-16 住友化学株式会社 月経随伴症状の予防、改善又は緩和のための組成物
WO2023166548A1 (ja) * 2022-03-01 2023-09-07 アサヒグループホールディングス株式会社 女性更年期症状の改善剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4589483B2 (ja) * 2000-05-12 2010-12-01 花王株式会社 ニキビ予防治療剤

Similar Documents

Publication Publication Date Title
WO2006065889A3 (en) Compositions and methods for reducing the transmissivity of illnesses
EP2638905A3 (en) Biofilm treatment
WO2007137167A3 (en) Co-therapy for the treatment of epilepsy
JP2007508326A5 (ja)
JP2005325108A5 (ja)
WO2010091827A3 (de) Kosmetische zubereitung zur hautpflege
WO2009061431A3 (en) Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
WO2010062581A3 (en) A botanical composition for enhanced skin repair and uses thereof
WO2013180834A3 (en) Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for treatment of paroxysmal nocturnal hemoglobinuria
JP2012528856A5 (ja)
JP2012527438A5 (ja)
WO2005102309A3 (en) In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
JP2005290479A5 (ja)
WO2006012536A3 (en) Methods and compositions for treating lactose intolerance
WO2008099144A3 (en) Tgf-beta stimulant and further agent to reduce side effects
JP2010502718A5 (ja)
WO2005041878A3 (en) Compositions and methods for increasing hdl and hdl-2b levels
WO2006048261A3 (en) Oral solid dosage forms containing a low dose of estradiol
JP2017525738A5 (ja)
WO2005089489A3 (en) Use of relaxin to increase arterial compliance
WO2008037486A3 (en) Suspension concentrates for improving root uptake of agrochemically active compounds
WO2007037790A3 (en) Modified release famciclovir compositions
JP2017052778A5 (ja)
JP2007153752A (ja) 皮膚化粧料
TNSN08497A1 (fr) Composition nasale et buccale pour lutter contre le ronflement